Academe Learn
CBME Curriculum Preview

Page 18 of 18

FM10.{7-15,18-19,21,25-27,29} | Medical Law, Negligence, Consent & Research Ethics — PBL Case

CLINICAL SETTING

You are a group of final-year medical students attending a medicolegal grand round at a teaching hospital. The case is presented by the hospital's legal advisor. Mrs Shakuntala Rao, 52 years, was admitted for elective hysterectomy for fibroids. She had signed a standard consent form but was not specifically informed about the 1–2% risk of bladder injury during laparoscopic hysterectomy. Post-operatively she developed urinary incontinence due to an inadvertent bladder laceration that was repaired intra-operatively but not disclosed to her or her family until she raised complaints 3 days later. On further inquiry, it emerged that the hospital had been collecting tissue specimens from hysterectomy patients for the past 2 years for an ongoing research study without obtaining separate research consent. Mrs Rao's specimen had been included. The hospital argued that the standard surgical consent covered 'all tissue removed during the procedure'. Mrs Rao is also HIV-positive (diagnosed 5 years ago, on stable ART). Her HIV status was accessed from hospital records by the research team and included in a 'patient characteristics' dataset shared with a pharmaceutical company under a data-sharing agreement, without her knowledge.

Trigger 1: The Consent Problem

Mrs Rao's consent form reads: 'I consent to laparoscopic hysterectomy and any associated procedures required.' The risk of bladder injury was not discussed. She was handed the form 15 minutes before being wheeled into the OT. She signed it because 'the nurses said it was routine'. The bladder repair was technically adequate, but the non-disclosure post-operatively led to delayed initiation of appropriate bladder rehabilitation.

DISCUSSION POINTS

  • Was Mrs Rao's consent valid for the surgical procedure? Identify specifically which elements of valid consent were deficient and why.
  • Does the intra-operative bladder injury and the post-operative non-disclosure create separate potential legal claims? What doctrines apply to each?
Click to reveal Trigger 2: The Research Consent Violation (discuss previous trigger first!)

Trigger 2: The Research Consent Violation

The tissue research study was approved by the hospital IEC. The IEC approval noted that 'standard surgical consent covers tissue obtained during clinical care and may be used for research'. The study was non-interventional and the tissue was anonymised before analysis. The same IEC had not specifically discussed research consent waivers; the approval was given as an agenda item in a 10-minute slot.

DISCUSSION POINTS

  • Under ICMR 2017 guidelines, does standard surgical consent constitute valid research consent for tissue banking? What are the specific requirements for separate research consent?
  • The IEC granted approval without formally deliberating on consent waiver conditions. Was this procedurally valid? What is the IEC's duty under ICMR 2017 for non-interventional tissue research?
Click to reveal Trigger 3: The HIV Disclosure Breach (discuss previous trigger first!)

Trigger 3: The HIV Disclosure Breach

The pharmaceutical company received the dataset for 'research collaboration'. The dataset included coded patient IDs, age, diagnosis, ART regimen, and comorbidities. Mrs Rao's HIV status was identifiable from her ART regimen combined with her unique surgical diagnosis. She had never consented to disclosure of HIV status for research. The hospital argues the data-sharing agreement complied with IT Act provisions.

DISCUSSION POINTS

  • Does accessing and sharing Mrs Rao's HIV status without her consent violate the HIV and AIDS (Prevention and Control) Act 2017? What specific provisions apply?
  • Can the 'anonymised' research dataset defence succeed when re-identification is possible from a combination of variables? What legal and ethical principles govern this scenario?
Click to reveal Trigger 4: Remedies and Institutional Accountability (discuss previous trigger first!)

Trigger 4: Remedies and Institutional Accountability

Mrs Rao wishes to pursue all available legal remedies. She is asking about: (1) compensation for the bladder injury, (2) action against the hospital for research consent violation, (3) action for HIV status disclosure. She is also a healthcare worker and fears professional consequences if her HIV status becomes widely known.

DISCUSSION POINTS

  • Map out the legal forums and remedies available to Mrs Rao: Consumer Forum under CPA 2019, complaint under HIV Act 2017, NMC ethical complaint. Which forum provides what remedy?
  • What institutional systemic changes should the hospital implement to prevent recurrence? Discuss at least four specific process improvements related to consent, IEC oversight, and data governance.

Learning Issues

Research these questions and bring your findings to the discussion.

  1. [FM10.18] What are the Bolam test and Bolitho modification? How do they determine the standard of care in civil medical negligence?
  2. [FM10.19] What are the six elements of valid informed consent? What makes consent 'truly informed' regarding material risks?
  3. [FM10.8] How does the Consumer Protection Act 2019 apply to medical services? What are the available forums and remedies?
  4. [FM10.25] What are ICMR 2017 requirements for research involving human tissues? When can IEC waive consent for tissue research?
  5. [FM10.27] What is the composition and function of an Institutional Ethics Committee? What are its duties under ICMR 2017?
  6. [FM10.7] What does the HIV and AIDS (Prevention and Control) Act 2017 say about disclosure of HIV status? What are the permitted exceptions?